IMPACT OF SWALLOWING THERAPY IN MANAGEMENT OF DYSPHAGIA POST RADIOTHERAPY

PILOT STUDY TO EVALUATE THE IMPACT OF PROPHYLACTIC SWALLOWING THERAPY ON DYSPHAGIA IN HEAD AND NECK CANCER PATIENTS UNDERGOING RADICAL CHEMORADIOTHERAPY

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024828

Enrollment

Registered

2020-04-23

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C00-C14- Malignant neoplasms of lip, oral cavity and pharynx

Interventions

Intervention1: PROPHYLACTIC SWALLOWING THERAPY DURING AND AFTER RADICAL CHEMORADIOTHERAPY: VMAT 66-70Gy IN 33-35 fractions by RAPID ARC technique with concurrent 3 weekly cisplatin 100mg/m2 along with

Eligibility

Inclusion criteria

Inclusion criteria: a) Biopsy proven oropharyngeal, hypopharyngeal and oral cavity cancers b) Stage III - IV disease treated with radical intent c) Karnofsky performance scale > 70 d) Patients giving written consent to be part of study

Exclusion criteria

Exclusion criteria: a) Metastatic disease b) Post operative cases c) Patients with pre existing swallowing disorders or neurological disorders interfering with swallowing. d) Previously treated patients

Design outcomes

Primary

Measure	Time frame
1) To document the baseline and treatment related dysphagia in patients under study 2) To evaluate the impact of swallowing therapy on incidence and grade of dysphagia between the study groupsTimepoint: BASELINE, 1,3 AND 6 MONTHS POST RT	—

Secondary

Measure	Time frame
To evaluate the quality of life with and without swallowing therapy between the two study groups.Timepoint: BASELINE, 1,3 AND 6 MONTHS POST RT	—

Countries

India

Contacts

Public ContactDr ROSHAN N

PGIMER

starroshanrockz@gmail.com7736189821

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026